Abstract
Anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) is an aggressive disease whose prognosis is changing due to the availability of second-generation ALK inhibitors. This study estimated the impact of brigatinib as monotherapy for the first-line treatment of adult patients with ALK+ advanced NSCLC on the Italian National Health System (NHS) budget.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call